==Silvercrest Asset Management (SAMG)

Silvercrest Asset Management Group Inc. completed its initial public offering on June 27, 2013, trading on the NASDAQ under the ticker symbol SAMG.

Founded in 2002, the New York-based wealth management firm focuses on ultra-high-net-worth individuals, families, and institutional investors.

IPO and Offering Details

Date: June 27, 2013 (effective June 26, 2013)
Exchange / Ticker: NASDAQ: SAMG
Shares Offered: ~4.8 million shares
Price Range: $12 to $14 per share
Capital Raised: ~$62 million
Lead Underwriters: Sandler O’Neill + Partners and Raymond James

Initial Delay: Silvercrest initially filed for a $55 million IPO in September 2012, but formally withdrew it in November 2012 citing unfavorable market valuations.

==Attovia Therapeutics Inc. has filed for an IPO

Attovia Therapeutics Inc. is seeking to raise up to $212.5 million in a U.S. initial public offering by offering 12.5 million shares priced at $15 to $17 each. The San Carlos, California-based biotech firm plans to list on the Nasdaq under the ticker symbol ATTO. 

Attovia to take on Sanofi and Regeneron’s Dupixent

Galderma won FDA approval for an IL-31 drug, Nemluvio, in 2024 and doubled its peak sales forecast to more than $4 billion this year. The drug, which Galderma licensed from Roche’s Chugai in 2016, fights with products including Dupixent for the atopic dermatitis and prurigo nodularis markets.

IPO Details & Terms

Shares offered: 12.5 million common shares
Price range: $15 to $17 per share
Target raise: Up to $212.5 million (or roughly $244.4 million if underwriters exercise options)
Exchange / Ticker: Nasdaq Global Market under ATTO
Joint Bookrunners: Morgan Stanley, Leerink Partners, Citigroup, RBC Capital Markets, and LifeSci Capital.

 Company Focus & Pipeline

Focus: Early-stage biopharmaceutical developer targeting immune-mediated inflammatory diseases. 
Platform: Uses a proprietary "ATTOBODY" platform in-licensed from Alamar Biosciences. 
Lead Candidate: ATTO-1310, an IL-31 inhibitor designed as a potential competitor to established treatments like Dupixent and Nemluvio for high-itch atopic dermatitis and chronic pruritus. 
Financial Position: Pre-revenue clinical-stage company reporting a net loss of $18.7 million for the first quarter of 2026. Proceeds from the IPO will fund upcoming Phase 2 clinical trials and pipeline expansion.

==RoboStrategy (BOT) : 2-month performance

 RoboStrategy, Inc. debuted on the public market on May 11, 2026, listing on the NASDAQ under the ticker symbol BOT. Rather than a standard operating company IPO, it launched as a specialized closed-end investment fund.

• https://robostrategy.co/

Fund Structure and Purpose

Vehicle Type: Closed-end management investment company.
Core Objective: Provides public market and retail investors access to private, pre-IPO, and public robotics and physical AI companies.
Investment Access: Targets high-profile robotics startups that have historically been restricted to venture capital funds.

Portfolio Holdings

Featured Startups: Includes private sector leaders such as Figure AI, Apptronik, Standard Bots, Dyna Robotics, and Dexmate.
Strategy: Focuses on a high-conviction portfolio of 20 to 30 positions concentrated on hardware, humanoids, and physical artificial intelligence.

LiveWire Group (LVWR) : 4-year performance

 

LiveWire Group went public on September 27, 2022, via a $1.8 billion

 merger with a special-purpose acquisition company (SPAC). 

• The company, formerly a Harley-Davidson electric motorcycle division, was spun off from its parent and became publicly traded on the New York Stock Exchange. 
• It is the first publicly traded electric motorcycle company in the United States.
• Ticker symbol: LVWR

 

 

 

Harley-Davidson spun off its electric motorcycle division, LiveWire, in a SPAC deal creating the first publicly traded electric motorcycle company in the United States.
 

Womenswear retailer Reformation files for IPO

July 20 (Reuters) - Permira-backed womenswear retailer Reformation is targeting a valuation of up to $1 billion in its U.S. initial public offering, marking a rare ​public-market foray for a fashion brand in recent years.

• The Vernon, California-based ‌company said on Monday it and some of its selling shareholders aim to raise up to $239.1 million in the IPO by offering 14.1 million shares priced between $15 and $17 each.
• Employees:    1261 
• Founded:    2009 
• http://www.thereformation.com/ 

Name of issuer:	Reformation Inc.
Last filed shares:	14,062,500
Last filed price:	$15.00 - $17.00

Industry:    APPAREL - Women's Juniors & Misses Outerwear
Market Cap    $945.28mil
Revenues    $533.31 mil (last 12 months)
Net Income    $-5.06 mil (last 12 months)

 

Founder Yael Aflalo 

 

 

Kendall Jenner wears Reformation dress in NYC
 

Founded in 2009 as a vintage clothing boutique in Los Angeles, Reformation was acquired by private equity firm Permira in 2019, which is expected to retain a significant stake following the IPO.

The brand describes itself as the world's largest sustainable womenswear brand. It operates 70 stores across the US, UK, Canada and France, while serving customers in more than 150 countries through its e-commerce business. Around 90% of sales are generated through its direct-to-consumer channels.

A public listing has been under consideration for several years. Bloomberg reported in May 2023 that Reformation was exploring an IPO after annual revenue surpassed $300 million.

More recently, revenue for the year ended 27 December 2025 rose to $507.1 million from $438.2 million a year earlier, while net profit declined to $12.6 million from $33 million. Gross margin for 2025 was 60.2%, down 360 basis points due to IEEPA tariffs.

Jersey Mike's Subs filed for an IPO

Jersey Mike's Subs and its existing investors have filed for an initial public offering (IPO) on the NYSE, targeting a valuation of up to $8 billion. The company aims to raise up to $1.09 billion by offering shares between $21.00 and $25.00 under the ticker symbol JMKE. 

• https://www.jerseymikes.com/ 

IPO Details

Expected Share Price: $21 to $25 per share
Ticker Symbol: JMKE
Listing Exchange: New York Stock Exchange (NYSE)
Target Capital Raised: Up to $1.09 billion (including secondary share sales from backers like Blackstone)
Underwriters: Morgan Stanley, Jefferies, and J.P. Morgan

Key Financials & Corporate Structure

Systemwide Sales: Hit $4.3 billion in 2025, marking a 13% increase.
Revenues & Profit: Reported net income of $55 million on $724 million in revenue.
Ownership Control: Private equity firm Blackstone (which bought a majority stake in early 2025) and existing stockholders are cashing out roughly 68% of the offering, but they will retain nearly two-thirds of the voting power post-IPO.

Latigo Biotherapeutics filed for an IPO

Latigo Biotherapeutics, a Thousand Oaks, California-based developer of non-opioid pain medicines, filed for an IPO with the SEC on July 17, 2026. The clinical-stage biotechnology company plans to raise $100 million and list on the Nasdaq under the ticker symbol LTGO. 

The Blue Owl Capital Inc.-backed clinical-stage developer of non-opioid pain medicines has one drug candidate in late-stage trials that has shown a roughly 50% greater analgesic effect than Vicodin, a comparable opioid, according to its filing Friday with the US Securities and Exchange Commission.

Key IPO Details

Ticker Symbol: LTGO
Target Exchange: Nasdaq Global Select Market
Underwriters: Goldman Sachs, Jefferies, Leerink Partners, and Guggenheim Securities
Target Amount: Approximately $100 million
Pipeline Highlights: The company is advancing LTG-001 (for acute pain) and LTG-321 (for osteoarthritis). Their lead candidate has shown a roughly 50% greater analgesic effect compared to the opioid Vicodin in trials.